AND ITS POTENTIAL APPLICATION TO HUMAN HYBRIDOMA TECHNOLOGY.

AND ITS POTENTIAL APPLICATION TO HUMAN HYBRIDOMA TECHNOLOGY.THIS PROJECT INVOLVES DETERMINING THE ABILITY OF A NEW CLASS OF SYNTHETIC BIOLOGICAL RESPONSE MODIFIERS (BRM) KNOWN AS METHYLFURYLBUTYROLACTONES (MFBL) TO AUGMENT THE PRODUCTION OF LYMPHOKINES (IL-2, B-CELL GROWTH FACTOR, AND IMMUNE INTERFERON) AND MONOKINES (IL-1, PROSTAGLANDINS, AND CYTOLYTIC FACTOR). OUR LABORATORY HAS DETERMINED THAT THE MFBLS ARE POTENT IMMUNOSTIMULATORY COMPOUNDS. MFBLS ARE CAPABLE OF INCREASING THE FOLLOWING IMMUNE FUNCTIONS: 2.PRIMARY AND SECONDARY ANTIBODY PRODUCTION 3.PHAGOCYTOSIS BY BOTH MACROPHAGES AND PMNS. IT IS KNOWN THAT THE ABOVE MENTIONED IMMUNE FUNCTIONS ARE REGULATED IN SOME WAY BY LYMPHOKINES AND/OR MONOKINES. THEREFORE, WE PLAN TO INVESTIGATE THE POSSIBILITY THAT MFBLS ENHANCE THESE IMMUNE FUNCTIONS BY STIMULATING AN INCREASED PRODUCTION OF LYMPHOKINES AND/OR MONOKINES. THIS HYPOTHESIS WILL BE TESTED BOTH IN VIVO AND IN VITRO USING ESTABLISHED MURINE LYMPHOKINE AND MONOKINE ASSAY SYSTEMS.